Gujarat Terce Laboratories Ltd (GUJTERC)

Loading page…

Gujarat Terce Laboratories Ltd (GUJTERC) · mywealthgrid

About

Gujarat Terce Laboratories Ltd operates in Pharmaceuticals within the Healthcare sector.

Face value: ₹10

Market cap

₹27 Cr

P/E

—

P/B

2.8×

Dividend yield

ROE

27.1%

ROCE

30.8%

Debt / equity

0.13

OPM

7.9%

EPS (TTM)

₹-3.2

Book value

₹12.5

52-week high

—

52-week low

—

1,851 historical price candles were omitted because the exchange source has not been verified.

₹35.2-3%1Y

Quick read

rule-based

Pros

+High return on capital employed of 25.7%
+Comfortable interest coverage of 20.3×

Cons

−Low return on equity of 5.4% (3-yr avg)
−Thin operating margin of 7.9%

Research score

Structured signal from quality, growth, valuation and momentum.

56/100

Business quality: 75
Growth: 1
Valuation: 92

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Standalone figures · ₹ crore · years without a filed annual are summed from quarters

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	25	26	29	31	38	25	40	47	48	50	47
COGS	-10	-8	-11	-12	-14	10	15	19	18	19	17
Gross profit	—	—	—	—	—	15	25	27	30	31	30
	34	33	39	42	51	18	24	30	29	27	27
	0	1	0	0	1	-3	1	-2	1	4	4
OPM %	1.4%	2%	1.1%	1.6%	1.8%	-11%	2.8%	-4.6%	2.7%	7.8%	7.9%
Depreciation	0	0	0	0	0	0	0	0	0	0	0
Interest	0	0	0	0	0	0	0	1	1	0	0
	—	—	0	0	—	1	0	0	0	0	-0
Profit before tax	-0	0	0	0	0	-3	1	-3	1	3	3
Tax	—	—	—	—	—	-0	-0	-1	0	4	1
Tax %	—	—	—	—	—	-0.4%	-17.3%	-42.2%	55.6%	128.9%	27.4%
	-1	-0	0	0	0	-3	1	-2	0	-1	2
PAT margin %	-2.7%	-1.2%	0.9%	1.4%	0.8%	-10%	2.2%	-3.6%	0.5%	-2%	4.6%
EPS (₹)	—	—	—	—	—	-3.4	1.2	-2.3	0.3	-2.6	2.9
EPS adjusted (₹)	—	—	—	—	0.4	-3.4	1.2	-2.3	0.3	-1.3	2.8
Annual report	Annual report for Mar 2016	Annual report for Mar 2017	Annual report for Mar 2018	Annual report for Mar 2019	Annual report for Mar 2020	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	Annual report for Mar 2026

₹ Cr	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	7	7	7	7	7	7	8
Reserves	—	0	1	-1	-0	-1	2
	—	5	6	6	4	1	1
	—	10	13	15	12	15	14
Total equity & liabilities	—	22	27	29	23	23	25
	2	2	4	4	4	4	3
CWIP	—	—	—	—	0	0	—
Investments	—	0	0	0	0	1	1
	—	19	23	24	19	19	20
Total assets	—	22	27	29	23	23	25

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Standalone figures

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	—	—	60.3%	62%	58.6%	63.1%	62.3%	63.9%
EBITDA margin %	1.6%	1.8%	-11%	2.8%	-4.6%	2.7%	7.8%	7.9%
EBIT margin %	0.9%	1.2%	-11.7%	2.1%	-5.4%	1.9%	7%	7%
PAT margin %	1.4%	0.8%	-10%	2.2%	-3.6%	0.5%	-2%	4.6%
Working capital
Receivable days	—	—	75	50	62	43	37	37
Inventory days	—	—	137	154	84	82	71	79
Payable days	—	—	104	96	110	97	70	34
NWC days	—	—	107	107	36	28	38	83
Leverage
Current ratio	—	—	1.03	1.17	0.97	0.92	0.95	1.32
Debt to EBITDA	—	—	—	5.42	—	3.05	0.24	0.35
Debt to equity	—	—	0.6	0.71	0.94	0.54	0.15	0.13
Interest coverage	2.4	1.6	-5.5	2.9	-3	1.8	9.1	20.3
Asset turnover	—	—	1.15	1.47	1.64	2.06	2.2	1.93
Return ratios
Return on assets %	—	—	-11.5%	3.2%	-5.9%	1%	-4.3%	9%
Return on capital employed %	—	—	-21.1%	9.4%	-16.6%	10.6%	35.8%	30.8%
Return on equity %	—	—	-32.9%	10.2%	-24.3%	3.4%	-15.1%	22.6%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	36.78%	37.01%	37.03%	37.03%	37.03%	37.03%	37.03%	37.03%	37.03%	40.03%	40.03%	40.03%
FII	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
DII	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	63.22%	62.99%	62.97%	62.97%	62.97%	62.97%	62.97%	62.97%	62.97%	59.97%	59.97%	59.97%
No. of shareholders	—	—	—	—	—	—	—	—	13,812	13,805	13,750	13,755

Promoter holding up 3.25 percentage points since Sep 2023.

17 deals · 1 Nov 2021 – 26 Jun 2025

Date	Client	Type	Venue	Side	Quantity	Price	Value
26 Jun 2025	NELVIN GEORGE	Bulk	BSE	Sell	40,212	₹51.37	₹0.21 Cr
15 Apr 2024	MABLE RAJESH	Bulk	BSE	Buy	73,000	₹52.40	₹0.38 Cr
17 Nov 2023	DHANPAT M KOTHARI	Bulk	BSE	Buy	44,772	₹24.92	₹0.11 Cr
15 Nov 2022	RISHABH NEGI	Bulk	BSE	Buy	75,000	₹18.60	₹0.14 Cr
25 Aug 2022	GUPTA	Bulk	BSE	Sell	43,893	₹20.78	₹0.09 Cr
16 Jun 2022	RADHIKA RASTOGI	Bulk	BSE	Sell	71,782	₹32.92	₹0.24 Cr
16 Jun 2022	RADHIKA RASTOGI	Bulk	BSE	Buy	11	₹33.25	₹0.00 Cr
15 Jun 2022	SATYA PRAKASH MITTAL HUF	Bulk	BSE	Sell	1,19,846	₹34.10	₹0.41 Cr
3 Jun 2022	SATYA PRAKASH MITTAL HUF	Bulk	BSE	Sell	44,699	₹42.21	₹0.19 Cr
3 Jun 2022	SATYA PRAKASH MITTAL HUF	Bulk	BSE	Buy	1,286	₹40.90	₹0.01 Cr

1–10 of 17

1 / 2

Mr. Natwarbhai PrajapatiExecutive Director-Chairperson related to Promoter
Mr. Aalap PrajapatiManaging Director & CEO
Mr. Amritbhai PrajapatiExecutive Director
Bhagirath R MauryaChief Financial Officer
Mr. Viplav S. KhamarNon-Executive - Independent Director
Mr. Surendrakumar P. SharmaNon-Executive - Independent Director
Mr. Navinchandra PatelNon-Executive - Independent Director
Ms. Avani Vishnubhai PatelDirector
Ms. Ashka SolankiCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

No fund holdings on record

No scheme among the 32 fund houses on record reported a position in Gujarat Terce Laboratories Ltd. Portfolios are published monthly by each AMC; coverage is still partial.

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

1

Board meeting to consider results7 Aug 2026

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

13 announcementsExport CSV

1 Aug 2026, 4:09 pmBoard Meeting

Board Meeting Intimation for Approving The Unaudited Standalone Financial Results Of The Company For The First Quarter Ended On 30 June 2026

Exchange filing PDF

30 Jul 2026, 4:13 pmCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

28 Jul 2026, 9:38 pmAGM/EGM

41St AGM Of The Shareholders Of Gujarat Terce Laboratories Limited Will Be Held On 21St August, 2026 At 12:00 Noon.

AGM PDF

28 Jul 2026, 8:24 pmOthers

Reg. 34 (1) Annual Report.

Reg. 34 (1) Annual Report PDF

14 Jul 2026, 9:22 amCompany Update

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 PDF

Date	Category	Subject	Filing
1 Aug 2026, 4:09 pm	Board Meeting	Board Meeting Intimation for Approving The Unaudited Standalone Financial Results Of The Company For The First Quarter Ended On 30 June 2026	PDF
30 Jul 2026, 4:13 pm	Company Update Newspaper Publication	Announcement under Regulation 30 (LODR)-Newspaper Publication

Loading announcements…

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	—	—	60.3%	62%	58.6%	63.1%	62.3%	63.9%
EBITDA margin %	1.6%	1.8%	-11%	2.8%	-4.6%	2.7%	7.8%	7.9%
EBIT margin %	0.9%	1.2%	-11.7%	2.1%	-5.4%	1.9%	7%	7%
PAT margin %	1.4%	0.8%	-10%	2.2%	-3.6%	0.5%	-2%	4.6%
Working capital
Receivable days	—	—	75	50	62	43	37	37
Inventory days	—	—	137	154	84	82	71	79
Payable days	—	—	104	96	110	97	70	34
NWC days	—	—	107	107	36	28	38	83
Leverage
Current ratio	—	—	1.03	1.17	0.97	0.92	0.95	1.32
Debt to EBITDA	—	—	—	5.42	—	3.05	0.24	0.35
Debt to equity	—	—	0.6	0.71	0.94	0.54	0.15	0.13
Interest coverage	2.4	1.6	-5.5	2.9	-3	1.8	9.1	20.3
Asset turnover	—	—	1.15	1.47	1.64	2.06	2.2	1.93
Return ratios
Return on assets %	—	—	-11.5%	3.2%	-5.9%	1%	-4.3%	9%
Return on capital employed %	—	—	-21.1%	9.4%	-16.6%	10.6%	35.8%	30.8%
Return on equity %	—	—	-32.9%	10.2%	-24.3%	3.4%	-15.1%	22.6%

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	-0	-0	0	3	3	2
	-0	-1	1	-0	0	-0
	2	2	-0	-4	-3	0
Net cash flow	1	0	1	-2	1	2
Free cash flow	-1	-3	-0	3	3	2
CFO / Operating profit %	—	-39.3%	—	204.7%	78.7%	45.7%

Gujarat Terce Laboratories Ltd

About

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Ratios

Shareholding

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Events

1

Announcements

Not in the F&O segment

No fund holdings on record

1

Announcements

Annual reports

Compounded sales growth

Compounded profit growth

Return on equity

Gujarat Terce Laboratories Ltd

About

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Events

Board meetings1

Announcements

Ratio timeline

Not in the F&O segment

No fund holdings on record

Board meetings1

Quarterly record

Bulk & block deals

Board and management

Announcements

Annual reports

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

1

1